Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn&apos;s Disease: Interim Results from the SEQUENCE Open-Label Extension Study

Inflammatory Bowel Disease

Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension Study

J Crohns Colitis

Loftus EV Jr, D'Haens G, Louis E, Regueiro M, Jairath V, Magro F, Nakase H, Dubcenco E, Lacerda AP, Ford S, Feng T, Duncan B, Fish I, Cunneen C, Anyanwu SI, Aponte F, Griffith J, Blumenstein I

doi: 10.1093/ecco-jcc/jjaf138

Inflammatory Bowel Disease

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study

Gastroenterology

Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G

doi: 10.1053/j.gastro.2025.02.033

Inflammatory Bowel Disease

Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study

Lancet Gastroenterol Hepatol

Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S

doi: 10.1016/S2468-1253(25)00017-2

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Inflammatory Bowel Disease

Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 study

Am J Gastroenterol

Lee SD, Vermeire S, Ungaro R, Vadhariya A, Durand F, Morris N, Yu G, Fisher DA, Traxler K, Long M

doi: 10.14309/ajg.0000000000003410

Inflammatory Bowel Disease

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)

J Crohns Colitis

Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB

doi: 10.1093/ecco-jcc/jjaf060

Inflammatory Bowel Disease

Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study

Lancet Gastroenterol Hepatol

D'Haens GR, Löwenberg M, Baert F, Bossuyt P, Molnár T, Hoentjen F, Clasquin E, Gecse KB, Hulshoff MS, De Hertogh G, Lenfant M, Oldenburg L, Vermeire S

doi: 10.1016/S2468-1253(25)00233-X

Inflammatory Bowel Disease

Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn's disease: A prospective observational study

Clin Gastroenterol Hepatol

Louis E, Sebastian S, Siegmund B, Bossuyt P, Danese S, de Boer N, Loftus EV, Moum B, Peyrin-Biroulet L, Schreiber S, Zhou J, Angellotti E, Adsul S, Jones S, Siegel CA

doi: 10.1016/j.cgh.2025.10.006

COMMENTED

Esophagus Diseases

Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: an Open-Label Extension Study

★ 3 Recommended and commented by Prof. Dr Stephan Vavricka, Faculty Member

Clin Gastroenterol Hepatol

Biedermann L, Schlag C, Straumann A, Lucendo AJ, Miehlke S, Vieth M, Santander C, Ciriza de Los Rios C, Schmöcker C, Madisch A, Hruz P, Hayat J, von Arnim U, Bredenoord AJ, Schubert S, Halstead M, Pfurr S, Mueller R, Schoepfer AM, Attwood S, International EOS-2 Study Group

doi: 10.1016/j.cgh.2024.10.034

Related content

Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension Study

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study

Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 study

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)

Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study

Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn's disease: A prospective observational study

Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: an Open-Label Extension Study